Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism

Cancer Chemotherapy and Pharmacology

Volumn 56, Issue 4, 2005, Pages 370-378

  De Jonge, Milly E ^a   Huitema, Alwin D R ^a   Holtkamp, Marjo J ^b   Van Dam, Selma M ^a   Beijnen, Jos H ^a,b   Rodenhuis, Sjoerd ^b  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Aprepitant; Cyclophosphamide; Nausea; Pharmacokinetic drug drug interaction; Thiotepa; Vomiting

Indexed keywords

4 HYDROXYCYCLOPHOSPHAMIDE; ANTIEMETIC AGENT; APREPITANT; CARBOPLATIN; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; CYTOCHROME P450 2B6; CYTOCHROME P450 3A4; CYTOCHROME P450 INHIBITOR; CYTOCHROME P450 ISOENZYME; DEXAMETHASONE; DRUG METABOLITE; FLUCONAZOLE; FOLIC ACID; GRANISETRON; PHYTOMENADIONE; RANITIDINE; TEPA; THIOTEPA;

ADVANCED CANCER; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ACTIVATION; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG EXPOSURE; DRUG INHIBITION; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG SCREENING; EXPERIENCE; FEMALE; FREQUENCY ANALYSIS; GERM CELL TUMOR; HUMAN; IC 50; LIVER MICROSOME; MALE; METASTASIS; NAUSEA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; POPULATION; PRIORITY JOURNAL; PROTECTION; STANDARD; VOMITING;

ANTIEMETICS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARBOPLATIN; CYCLOPHOSPHAMIDE; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; MICROSOMES, LIVER; MORPHOLINES; NAUSEA; NEOPLASMS, GERM CELL AND EMBRYONAL; THIOTEPA;

EID: 22344440053     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-005-1005-4     Document Type: Article

References (32)

1. Beal SL, Sheiner LB (1998) User's Guides, NONMEM Project Group. University of California at San Francisco, San Francisco
2. Chang TKH, Weber GF, Crespi CL, Waxman DJ (1993) Differential activation of cyclophosphamide and ifosfamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res 53:5629-5637
3. 32P-labelled triethylenephosphoramide in relation to its anti-tumour activity. Br J Pharmacol 10:321-325
4. Dando TM, Perry CM (2004) Aprepitant. A review of its use in the prevention of chemotherapy-induced nausea and vomiting. Drugs 64:777-794
5. De Jonge ME, Huitema ADR, Rodenhuis S, Beijnen JH (2004) Integrated population pharmacokinetic model of both cyclophosphamide and thiotepa suggesting a mutual drug-drug interaction. J Pharmacokin Pharmacodyn 31:135-156
6. De Jonge ME, Van Dam SM, Hillebrand MJX, Rosing H, Huitema ADR, Rodenhuis S, Beijnen JH (2004) Simultaneous quantification of cyclophosphamide, 4-hydroxycyclophosphamide, N ,N′ ,N″ -triethylenethiophosphoramide (thiotepa) and N,N′ ,N″ -triethylenephosphoramide (tepa) in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry (LC-MS/MS). J Mass Spectrom 39:233-254
7. De Wit R, Herrstedt J, Rapoport B, Carides AD, Carides G, Elmer M, Schmidt C, Evans JK, Horgan KJ (2003) Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. J Clin Oncol 21:4105-4111
8. 1 antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomized, placebo-controlled phase II clinical trials. Eur J Cancer 40:403-410
9. Gervot L, Rochat B, Gautier JC, Bohnenstengel F, Kroemer H, de Berardinis V, Martin H, Beaune P, de Waziers I (1999) Human CYP2B6: expression, inducibility and catalytic activities. Pharmacogenetics 9:295-306
10. Heideman RL, Cole DE, Balis F, Sato J, Reaman GH, Packer RJ, Singher LJ, Ettinger LJ, Gillespie A, Sam J et al (1989) Phase I and pharmacokinetic evaluation of thiotepa in the cerebrospinal fluid and plasma of pediatric patients: evidence for dose-dependent plasma clearance of thiotepa. Cancer Res 49:736-741
11. Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R, Chawla SP, Carides AD, Ianus J, Elmer ME, Evans JK, Beck K, Reines S, Horgan KJ Aprepitant Protocol 052 Study Group (2003) The oral neurokin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin. The aprepitant protocol 052 study group. J Clin Oncol 21:4112-4119
12. Huitema ADR, Kerbusch T, Tibben MM, Rodenhuis S, Beijnen JH (2000) Reduction of cyclophosphamide-bioactivation by thiotepa: critical sequence-dependency in high-dose chemotherapy regimens. Cancer Chemother Pharmacol 46:119-127
13. Huitema ADR, Spaander M, Mathôt RAA, Tibben MM, Holtkamp MJ, Beijnen JH, Rodenhuis S (2002) Relationship between exposure and toxicity in high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin. Ann Oncol 13:374-384
14. Jacobson PA, Green K, Birnbaum A, Remmel RP (2002) Cytochrome P450 isozymes 3A4 and 2B6 are involved in the in vitro human metabolism of thiotepa to tepa. Cancer Chemother Pharmacol 49:461-467
15. Lindley C, Hamilton G, McCune JS, Faucette S, Shord SS, Hawke RL, Wang H, Gilbert D, Jolley S, Yan B, LeCluyse EL (2002) The effect of cyclophosphamide with and without dexamethasone on cytochrome P450 3A4 and 2B6 in human hepatocytes. Drug Metab Dispos 30:814-822
16. Majumdar AK, McCrea JB, Panebianco DL, Hesney M, Dru J, Constanzer M, Goldberg MR, Murphy G, Gottesdiener KM, Lines CR, Petty KJ, Blum RA (2003) Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probe. Clin Pharmacol Ther 74:150-156
17. Martin H, Sarsat JP, De Waziers I, Housset C, Balladur P, Beaune P, Albaladejo V, Lerche-Langrand C (2003) Induction of cytochrome P450 2B6 and 3A4 expression by phenobarbital and cyclophosphamide in cultured human liver slices. Pharm Res 20:557-568
18. McCrea JB, Majumar AK, Goldberg MR, Iwamoto M, Gargano C, Panebianco DL, Hesney M, Lines CR, Petty KJ, Deutsch PJ, Murphy MG, Gottesdiener KM, Goldwater DR, Blum RA (2003) Effects of the neurokin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone. Clin Pharmacol Ther 74:17-24
19. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Julie Ma G, Eldridge K, Hipple A, Evans JK, Horgan KJ, Lawson F; Aprepitant Protocol 054 Study Group (2003) Addition of the neurokin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 97:3090-3098
20. Product information: Emend(aprepitant) capsules. Merck&-Co., Inc., March 2003
21. Ren S, Yang JS, Kalhorn TF, Slattery JT (1997) Oxidation of cyclophosphamide to 4-hydroxycyclophosphamide and deschloroethylcyclophosphamide in human liver microsomes. Cancer Res 57:4229-4235
22. Roy P, Yu LJ, Crespi CL, Waxman DJ (1999) Development of a substrate activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab Dispos 27:655-666
23. Rodenhuis S, Bontenbal M, Beex LV, Wagstaff J, Richel DJ, Nooij MA, Voest EE, Hupperets P, van Tinteren H, Peterse HL, TenVergert EM, de Vries EGE, Netherlands Working Party on Autologous Transplantation in Solid Tumors (2003) High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. N Engl J Med 349:7-16
24. Rodenhuis S, de Wit R, de Mulder PH, Keizer HJ, Sleijfer DT, Lalisang RI, Bakker PJ, Mandjes I, Kooi M, de Vries EGE (1999) A multi-center prospective phase II study of high-dose chemotherapy in germ-cell cancer patients relapsing from complete remission. Ann Oncol 10:1467-1473
25. Rodenhuis S, Westermann A, Holtkamp MJ, Nooijen WJ, Baars JW, Van der Wall E, Slaper-Cortenbach IC, Schornagel JH (1996) Feasibility of multiple courses of high-dose cyclophosphamide, thiotepa, and carboplatin for breast cancer or germ cell cancer. J Clin Oncol 14:1473-1483
26. Schrama JG, Holtkamp MJ, Baars JW, Schornagel JH, Rodenhuis S (2003) Toxicity of the high-dose chemotherapy CTC regimen (cyclophosphamide, thiotepa, carboplatin): the Netherlands Cancer Institute experience. Br J Cancer 88:1831-1838
27. Shadle CR, Lee Y, Majumdar AK, Petty KJ, Gargano C, Bradstreet TE, Evans JK, Blum RA (2004) Evaluation of potential inductive effects of aprepitant on cytochrome P450 3A4 and 2C9 activity. J Clin Pharmacol 44:215-223
28. Teicher BA, Waxman DJ, Holden SA, Wang YY, Clarke L, Alvarez Sotomayor E, Jones SM, Frei E III (1989) Evidence for enzymatic activation and oxygen involvement in cytotoxicity and anti-tumor activity of N,N′ ,N″ -Triethylenethiophosphoramide. Cancer Res 49:4996-5001
29. Van Maanen MJ, Huitema ADR, Beijnen JH (2000) Influence of co-medicated drugs on the biotransformation of thiotepa to tepa and thiotepa-mercapturate. Anticancer Res 20:1711-1716
30. Van Warmerdam LJC, Van Tellingen O, Maes RAA, Beijnen JH (1995) Validated method for the determination of carboplatin in biological fluids by Zeeman atomic absorption spectrometry. Fresenius J Anal Chem 352:777-781
31. Warr DG, Eisenberg P, Hesketh PJ, Gralla RJ, Raftopolous H, Gabriel M, Rodgers A, Klinger G, Hustad CM, Skobieranda F (2004) Effect of aprepitant for the prevention of nausea and vomiting after one cycle of moderately emetigenic chemotherapy: A randomized double-blind trial in 866 patients. Proc Am Soc Clin Oncol 23:abstract 8007
32. Yu L, Waxman J (1996) Role of cytochrome P450 in oxazaphosphorine metabolism. Deactivation via N-dechloroethylation and activation via 4-hydroxylation catalyzed by distinct subsets of rat liver cytochromes P450. Drug Metab Dispos 24:1254-1262